<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37514997</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1181</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11071181</ELocationID><Abstract><AbstractText>Although the chief of the World Health Organization (WHO) has declared the end of the coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a global threat. To be able to manage such pandemics in the future, it is necessary to develop proper strategies and opportunities to protect human life. The data on the SARS-CoV-2 virus must be continuously analyzed, and the possibilities of mutation and the emergence of new, more infectious variants must be anticipated, as well as the options of using different preventive and therapeutic techniques. This is because the fast development of severe acute coronavirus 2 syndrome (SARS-CoV-2) variants of concern have posed a significant problem for COVID-19 pandemic control using the presently available vaccinations. This review summarizes data on the SARS-CoV-2 variants that are responsible for severe COVID-19 and the clinical efficacy of the most commonly used vaccines in clinical practice. The consequences after the disease (long COVID or post-COVID conditions) continue to be the subject of studies and research, and affect social and economic life worldwide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miteva</LastName><ForeName>Dimitrina</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5931-2426</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Faculty of Biology, Sofia University "St. Kliment Ohridski", 8 Dragan Tzankov str., 1164 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanova</LastName><ForeName>Meglena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6730-7387</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Faculty of Biology, Sofia University "St. Kliment Ohridski", 8 Dragan Tzankov str., 1164 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batselova</LastName><ForeName>Hristiana</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Disaster Medicine, University Hospital "Saint George", Medical University, 6000 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazova</LastName><ForeName>Snezhina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5884-7760</Identifier><AffiliationInfo><Affiliation>Pediatric Department, University Hospital "N. I. Pirogov," 21 "General Eduard I. Totleben" Blvd, 1606 Sofia, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Healthcare, Faculty of Public Health "Prof. Tsekomir Vodenicharov, MD, DSc", Medical University of Sofia, Bialo More 8 str., 1527 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chervenkov</LastName><ForeName>Lyubomir</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8380-5992</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Medical University Plovdiv, Bul. Vasil Aprilov 15A, 4000 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peshevska-Sekulovska</LastName><ForeName>Monika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8468-0132</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, University Hospital Lozenetz, 1407 Sofia, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Faculty, Sofia University St. Kliment Ohridski, 1407 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekulovski</LastName><ForeName>Metodija</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8374-7756</Identifier><AffiliationInfo><Affiliation>Medical Faculty, Sofia University St. Kliment Ohridski, 1407 Sofia, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, University Hospital Lozenetz, 1 Kozyak str., 1407 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulinac</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General and Clinical Pathology, Medical University of Plovdiv, Bul. Vasil Aprilov 15A, 4000 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasilev</LastName><ForeName>Georgi V</ForeName><Initials>GV</Initials><Identifier Source="ORCID">0000-0002-3280-5060</Identifier><AffiliationInfo><Affiliation>Clinic of Endocrinology and Metabolic Disorders, UMHAT "Sv. Georgi", 4000 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomov</LastName><ForeName>Luchesar</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1902-6473</Identifier><AffiliationInfo><Affiliation>Department of Informatics, New Bulgarian University, Montevideo 21 str., 1618 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velikova</LastName><ForeName>Tsvetelina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0593-1272</Identifier><AffiliationInfo><Affiliation>Medical Faculty, Sofia University St. Kliment Ohridski, 1407 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>project &#x2116; BG-RRP-2.004-0008-C01</GrantID><Agency>the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria,</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">effectiveness</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37514997</ArticleId><ArticleId IdType="pmc">PMC10385722</ArticleId><ArticleId IdType="doi">10.3390/vaccines11071181</ArticleId><ArticleId IdType="pii">vaccines11071181</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biancolella M., Colona V.L., Mehrian-Shai R., Watt J.L., Luzzatto L., Novelli G., Reichardt J.K.V. COVID-19 2022 update: Transition of the pandemic to the endemic phase. Hum. Genom. 2022;16:19. doi: 10.1186/s40246-022-00392-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-022-00392-1</ArticleId><ArticleId IdType="pmc">PMC9156835</ArticleId><ArticleId IdType="pubmed">35650595</ArticleId></ArticleIdList></Reference><Reference><Citation>Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic.  [(accessed on 29 May 2023)].  Available online:  https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(COVID-19)-pandemic?adgroupsurvey={adgroupsurvey}&amp;gclid=Cj0KCQjwmtGjBhDhARIsAEqfDEfx3ABO8vnrA5v_oZMuDPL7GkxwtT_jnI2owNdujJfxbZ88TGTwa5caAkZSEALw_wcB.</Citation></Reference><Reference><Citation>Gong W., Parkkila S., Wu X., Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int. Rev. Immunol. 2022:1&#x2013;22. doi: 10.1080/08830185.2022.2079642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2022.2079642</ArticleId><ArticleId IdType="pubmed">35635216</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  SARS-CoV-2 Variant Classifications and Definitions (updated 10 June 2021)  [(accessed on 10 October 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.</Citation></Reference><Reference><Citation>Rahman M.A., Islam M.S. Early approval of COVID-19 vaccines: Pros and cons. Hum. Vaccin. Immunother. 2021;17:3288&#x2013;3296. doi: 10.1080/21645515.2021.1944742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1944742</ArticleId><ArticleId IdType="pmc">PMC8437465</ArticleId><ArticleId IdType="pubmed">34283001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann G. Nucleic Acid Immunity. Adv. Immunol. 2017;133:121&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112058</ArticleId><ArticleId IdType="pubmed">28215278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Chen Z., Wang Z., Li J., Yan Z., Yuan J., Zhu A., Chen L., Liu Y., Hu C., et al. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. Emerg. Microbes Infect. 2022;11:1550&#x2013;1553. doi: 10.1080/22221751.2022.2081616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2081616</ArticleId><ArticleId IdType="pmc">PMC9176361</ArticleId><ArticleId IdType="pubmed">35604772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Zhu Y., Chu M. Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Front. Immunol. 2022;13:898192. doi: 10.3389/fimmu.2022.898192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.898192</ArticleId><ArticleId IdType="pmc">PMC9165056</ArticleId><ArticleId IdType="pubmed">35669787</ArticleId></ArticleIdList></Reference><Reference><Citation>CanSinoBIO&#x2019;s Convidecia Air&#x2122; Receives Approval in China.  [(accessed on 22 June 2023)].  Available online:  https://www.cansinotech.com/html/1///179/180/1100.html.</Citation></Reference><Reference><Citation>Beavis A.C., Li Z., Briggs K., Huertas-D&#xed;az M.C., Wrobel E.R., Najera M., An D., Orr-Burks N., Murray J., Patil P., et al. Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants. bioRxiv. 2022:Preprint. doi: 10.1101/2022.06.07.495215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.07.495215</ArticleId></ArticleIdList></Reference><Reference><Citation>Miteva D., Peshevska-Sekulovska M., Snegarova V., Batselova H., Alexandrova R., Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J. Virol. 2022;11:221&#x2013;236. doi: 10.5501/wjv.v11.i5.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i5.221</ArticleId><ArticleId IdType="pmc">PMC9523321</ArticleId><ArticleId IdType="pubmed">36188733</ArticleId></ArticleIdList></Reference><Reference><Citation>Afkhami S., D&#x2019;Agostino M.R., Zhang A., Stacey H.D., Marzok A., Kang A., Singh R., Bavananthasivam J., Ye G., Luo X., et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896&#x2013;915.e19. doi: 10.1016/j.cell.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8825346</ArticleId><ArticleId IdType="pubmed">35180381</ArticleId></ArticleIdList></Reference><Reference><Citation>Knisely J.M., Buyon L.E., Mandt R., Farkas R., Balasingam S., Bok K., Buchholz U.J., D&#x2019;Souza M.P., Gordon J.L., King D.F., et al. Mucosal vaccines for SARS-CoV-2: Scientific gaps and opportunities&#x2014;workshop report. npj Vaccines. 2023;8:53. doi: 10.1038/s41541-023-00654-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00654-6</ArticleId><ArticleId IdType="pmc">PMC10091310</ArticleId><ArticleId IdType="pubmed">37045860</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  COVID-19 Vaccine Tracker and Landscape.  [(accessed on 20 June 2023)].  Available online:  https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Jia Z., Gong W. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines? J. Korean Med. Sci. 2021;36:e124. doi: 10.3346/jkms.2021.36.e124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e124</ArticleId><ArticleId IdType="pmc">PMC8111046</ArticleId><ArticleId IdType="pubmed">33975397</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspatwar A., Gong W., Wang S., Wu X., Parkkila S. Tuberculosis vaccine BCG: The magical effect of the old vaccine in the fight against the COVID-19 pandemic. Int. Rev. Immunol. 2022;41:283&#x2013;296. doi: 10.1080/08830185.2021.1922685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.1922685</ArticleId><ArticleId IdType="pmc">PMC8108189</ArticleId><ArticleId IdType="pubmed">33960271</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 20 June 2023)].  Available online:  https://covid19.who.int.</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) Vaccinations.  [(accessed on 20 June 2023)].  Available online:  https://ourworldindata.org/covid-vaccinations.</Citation></Reference><Reference><Citation>Jiricny J. Postreplicative mismatch repair. Cold Spring Harb. Perspect. Biol. 2013;5:a012633. doi: 10.1101/cshperspect.a012633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a012633</ArticleId><ArticleId IdType="pmc">PMC3683899</ArticleId><ArticleId IdType="pubmed">23545421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanju&#xe1;n R., Domingo-Calap P. Mechanisms of viral mutation. Cell. Mol. Life Sci. 2016;73:4433&#x2013;4448. doi: 10.1007/s00018-016-2299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2299-6</ArticleId><ArticleId IdType="pmc">PMC5075021</ArticleId><ArticleId IdType="pubmed">27392606</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M., Ruggiero A., Squeglia F., Maga G., Berisio R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells. 2020;9:1267. doi: 10.3390/cells9051267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051267</ArticleId><ArticleId IdType="pmc">PMC7291026</ArticleId><ArticleId IdType="pubmed">32443810</ArticleId></ArticleIdList></Reference><Reference><Citation>Abavisani M., Rahimian K., Mahdavi B., Tokhanbigli S., Mollapour Siasakht M., Farhadi A., Kodori M., Mahmanzar M., Meshkat Z. Mutations in SARS-CoV-2 structural proteins: A global analysis. Virol. J. 2022;19:220. doi: 10.1186/s12985-022-01951-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01951-7</ArticleId><ArticleId IdType="pmc">PMC9759450</ArticleId><ArticleId IdType="pubmed">36528612</ArticleId></ArticleIdList></Reference><Reference><Citation>Badua C., Baldo K.A.T., Medina P.M.B. Genomic and proteomic mutation landscapes of SARS-CoV-2. J. Med. Virol. 2021;93:1702&#x2013;1721. doi: 10.1002/jmv.26548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26548</ArticleId><ArticleId IdType="pmc">PMC7537117</ArticleId><ArticleId IdType="pubmed">32970329</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza P.F.N., Mesquita F.P., Amaral J.L., Landim P.G.C., Lima K.R.P., Costa M.B., Farias I.R., Bel&#xe9;m M.O., Pinto Y.O., Moreira H.H.T., et al. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. Int. J. Biol. Macromol. 2022;208:105&#x2013;125. doi: 10.1016/j.ijbiomac.2022.03.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.03.058</ArticleId><ArticleId IdType="pmc">PMC8920968</ArticleId><ArticleId IdType="pubmed">35300999</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul P., France A.M., Aoki Y., Batra D., Biggerstaff M., Dugan V., Galloway S., Hall A.J., Johansson M.A., Kondor R.J., et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020&#x2013;May 2021. Morb. Mortal. Wkly. Rep. 2021;70:846&#x2013;850. doi: 10.15585/mmwr.mm7023a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7023a3</ArticleId><ArticleId IdType="pmc">PMC8191868</ArticleId><ArticleId IdType="pubmed">34111060</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., Holmes E.C., O&#x2019;Toole &#xc1;., Hill V., McCrone J.T., Ruis C., du Plessis L., Pybus O.G. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020;5:1403&#x2013;1407. doi: 10.1038/s41564-020-0770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hilton S.K., Ellis D., Crawford K.H.D., Dingens A.S., Navarro M.J., Bowen J.E., Tortorici M.A., Walls A.C., et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182:1295&#x2013;1310.e20. doi: 10.1016/j.cell.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Plante K.S., Plante J.A., Xie X., Zhang X., Ku Z., An Z., Scharton D., Schindewolf C., et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602:294&#x2013;299. doi: 10.1038/s41586-021-04245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04245-0</ArticleId><ArticleId IdType="pmc">PMC8900207</ArticleId><ArticleId IdType="pubmed">34818667</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., VanBlargan L.A., Bloyet L.M., Rothlauf P.W., Chen R.E., Stumpf S., Zhao H., Errico J.M., Theel E.S., Liebeskind M.J., et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell. Host Microbe. 2021;29:477&#x2013;488.e4. doi: 10.1016/j.chom.2021.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.01.014</ArticleId><ArticleId IdType="pmc">PMC7839837</ArticleId><ArticleId IdType="pubmed">33535027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F., Tong B., Sun L., Shi S., Zheng B., Wang Z., Dong X., Zheng P. N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2. Elife. 2021;10:e69091. doi: 10.7554/eLife.69091.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.69091</ArticleId><ArticleId IdType="pmc">PMC8455130</ArticleId><ArticleId IdType="pubmed">34414884</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock T.P., Goldhill D.H., Zhou J., Baillon L., Frise R., Swann O.C., Kugathasan R., Penn R., Brown J.C., Sanchez-David R.Y., et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 2021;6:899&#x2013;909. doi: 10.1038/s41564-021-00908-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00908-w</ArticleId><ArticleId IdType="pubmed">33907312</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S., Harvey W.T., Lytras S., Mohamed A., Gallo G., et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell. Rep. 2021;35:109292. doi: 10.1016/j.celrep.2021.109292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pmc">PMC8185188</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Zhang J., He Q., Mao Q., Xu M., Liang Z. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert. Rev. Vaccines. 2021;20:365&#x2013;373. doi: 10.1080/14760584.2021.1903879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Zhang J., Xiao T., Lavine C.L., Rawson S., Peng H., Zhu H., Anand K., Tong P., Gautam A., et al. Structural Basis for Enhanced Infectivity and Immune Evasion of SARS-CoV-2 Variants. Science. 2021;373:642&#x2013;648. doi: 10.1126/science.abi9745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi9745</ArticleId><ArticleId IdType="pmc">PMC9245151</ArticleId><ArticleId IdType="pubmed">34168070</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., De Marco A., Ferreira I.A.T.M., Meng B., Datir R.P., Walls A.C., Kemp S.A., Bassi J., Pinto D., Silacci-Fregni C., et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136&#x2013;141. doi: 10.1038/s41586-021-03412-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03412-7</ArticleId><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara V.V., Floyd K., Lai L., Gardner M., Hudson W., Piantadosi A., Waggoner J.J., Babiker A., Ahmed R., Xie X., et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021:2021-02. doi: 10.1101/2021.02.02.21250799. preprint .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.02.21250799</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara V.V., Lai L., Sahoo M.K., Floyd K., Sibai M., Solis D., Flowers M.W., Hussaini L., Ciric C.R., Bechnack S., et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. 2021 doi: 10.1101/2021.05.09.443299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.09.443299</ArticleId><ArticleId IdType="pmc">PMC8279090</ArticleId><ArticleId IdType="pubmed">34233096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X., Tang H., McDanal C., Wagh K., Fischer W., Theiler J., Yoon H., Li D., Haynes B.F., Sanders K.O., et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv. 2021 doi: 10.1101/2021.01.27.428516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.428516</ArticleId><ArticleId IdType="pmc">PMC7934674</ArticleId><ArticleId IdType="pubmed">33705729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130&#x2013;135. doi: 10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Casner R.G., Nair M.S., Wang M., Yu J., Cerutti G., Liu L., Kwong P.D., Huang Y., Shapiro L., et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv. 2021 doi: 10.1016/j.chom.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8053237</ArticleId><ArticleId IdType="pubmed">33887205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Werner A.P., Moliva J.I., Koch M., Choi A., Stewart-Jones G.B.E., Bennett H., Boyoglu-Barnum S., Shi W., Graham B.S., et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021 doi: 10.1101/2021.01.25.427948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.25.427948</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim S., The 2nd COVID-19 Wave in South Africa: Transmissibility and a 501.V2 Variant  CAPRISA&#x2014;Centre for The Aids Programme of Research in South Africa. 2020.  [(accessed on 20 June 2023)].  Available online:  https://www.scribd.com/document/488618010/Full-Presentation-by-SSAK-18-Dec.</Citation></Reference><Reference><Citation>Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature. 2021;589:177&#x2013;178. doi: 10.1038/d41586-021-00031-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00031-0</ArticleId><ArticleId IdType="pubmed">33432212</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C., Muecksch F., Rutkowska M., Hoffmann H.H., Michailidis E., et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9:e61312. doi: 10.7554/eLife.61312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi C., Sun X., Ye J., Ding L., Liu M., Yang Z., Lu X., Zhang Y., Ma L., Gu W., et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell. Mol. Immunol. 2020;17:621&#x2013;630. doi: 10.1038/s41423-020-0458-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0458-z</ArticleId><ArticleId IdType="pmc">PMC7227451</ArticleId><ArticleId IdType="pubmed">32415260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., Ye C., Rathnasinghe R., Stadlbauer D., Krammer F., Simon V., Martinez-Sobrido L., Garcia-Sastre A., Schotsaert M. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021 doi: 10.1101/2021.01.26.21250543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.26.21250543</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Loes A.N., Crawford K.H.D., Starr T.N., Malone K.D., Chu H.Y., Bloom J.D. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell. Host Microbe. 2021;29:463&#x2013;476.e6. doi: 10.1016/j.chom.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Gazy I., Jackson L., Hwa S.H., Tegally H., Lustig G., Giandhari J., Pillay S., Wilkinson E., Naidoo Y., et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142&#x2013;146. doi: 10.1038/s41586-021-03471-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03471-w</ArticleId><ArticleId IdType="pmc">PMC9867906</ArticleId><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujino T., Nomoto H., Kutsuna S., Ujiie M., Suzuki T., Sato R., Fujimoto T., Kuroda M., Wakita T., Ohmagari N. Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan. Emerg. Infect. Dis. 2021;27:1243&#x2013;1245. doi: 10.3201/eid2704.210138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2704.210138</ArticleId><ArticleId IdType="pmc">PMC8007308</ArticleId><ArticleId IdType="pubmed">33567247</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria N.R., Mellan T.A., Whittaker C., Claro I.M., Candido D.D.S., Mishra S., Crispim M.A.E., Sales F.C.S., Hawryluk I., McCrone J.T., et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815&#x2013;821. doi: 10.1126/science.abh2644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2644</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabino E.C., Buss L.F., Carvalho M.P.S., Prete C.A., Jr., Crispim M.A.E., Fraiji N.A., Pereira R.H.M., Parag K.V., da Silva Peixoto P., Kraemer M.U.G., et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397:452&#x2013;455. doi: 10.1016/S0140-6736(21)00183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00183-5</ArticleId><ArticleId IdType="pmc">PMC7906746</ArticleId><ArticleId IdType="pubmed">33515491</ArticleId></ArticleIdList></Reference><Reference><Citation>Voloch C.M., da Silva Francisco R., Jr., de Almeida L.G.P., Cardoso C.C., Brustolini O.J., Gerber A.L., Guimar&#xe3;es A.P.C., Mariani D., da Costa R.M. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J. Virol. 2021;95:e00119-21. doi: 10.1128/JVI.00119-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00119-21</ArticleId><ArticleId IdType="pmc">PMC8139668</ArticleId><ArticleId IdType="pubmed">33649194</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Garcia-Knight M.A., Khalid M.M., Servellita V., Wang C., Morris M.K., Sotomayor-Gonz&#xe1;lez A., Glasner D.R., Reyes K.R., Gliwa A.S., et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426&#x2013;3437.e8. doi: 10.1016/j.cell.2021.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.025</ArticleId><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., De Marco A., Lempp F.A., Tortorici M.A., Pinto D., Walls A.C., Beltramello M., Chen A., Liu Z., Zatta F., et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332&#x2013;2347.e16. doi: 10.1016/j.cell.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchesnokova V., Kulasekara H., Larson L., Bowers V., Rechkina E., Kisiela D., Sledneva Y., Choudhury D., Maslova I., Deng K., et al. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. J. Clin. Microbiol. 2021;59:e0092121. doi: 10.1128/JCM.00921-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00921-21</ArticleId><ArticleId IdType="pmc">PMC8525575</ArticleId><ArticleId IdType="pubmed">34379531</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., Liu J., Mann S.A., Mitchell A.M., Laurie M.T., Sunshine S., Pilarowski G., Ayscue P., Kistler A., Vanaerschot M., et al. Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco. Clin. Infect. Dis. 2022;74:32&#x2013;39. doi: 10.1093/cid/ciab283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab283</ArticleId><ArticleId IdType="pmc">PMC8083548</ArticleId><ArticleId IdType="pubmed">33788923</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England  SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical Briefing 10.  [(accessed on 4 October 2022)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf.</Citation></Reference><Reference><Citation>Ozer E.A., Simons L.M., Adewumi O.M., Fowotade A.A., Omoruyi E.C., Adeniji J.A., Olayinka O.A., Dean T.J., Zayas J., Bhimalli P.P., et al. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. Nat. Commun. 2022;13:688. doi: 10.1038/s41467-022-28317-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28317-5</ArticleId><ArticleId IdType="pmc">PMC8813984</ArticleId><ArticleId IdType="pubmed">35115515</ArticleId></ArticleIdList></Reference><Reference><Citation>Annavajhala M.K., Mohri H., Wang P., Nair M., Zucker J.E., Sheng Z., Gomez-Simmonds A., Kelley A.L., Tagliavia M., Huang Y., et al. Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York. medRxiv. 2021 doi: 10.1101/2021.02.23.21252259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.23.21252259</ArticleId><ArticleId IdType="pmc">PMC8481122</ArticleId><ArticleId IdType="pubmed">34428777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasek-Nesselquist E., Lapierre P., Schneider E., George K., Pata J. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State. medRxiv. 2021 doi: 10.1101/2021.02.26.21251868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.26.21251868</ArticleId></ArticleIdList></Reference><Reference><Citation>West A., Barnes C., Yang Z., Bjorkman P. SARS-CoV-2 Lineage B.1.526 emerging in the New York region detected by software utility created to query the Spike mutational landscape. bioRxiv. 2021 doi: 10.1038/s41467-021-25168-4. Update in: Nat. Commun.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25168-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Thao T.T.N., Hoffmann D., Taddeo A., Ebert N., Labroussaa F., Pohlmann A., King J., Steiner S., Kelly J.N., et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592:122&#x2013;127. doi: 10.1038/s41586-021-03361-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03361-1</ArticleId><ArticleId IdType="pubmed">33636719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health and Family Welfare  Genome Sequencing by INSACOG Shows Variants of Concern and a Novel Variant in India.  [(accessed on 4 October 2022)]; Available online:  https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1707177.</Citation></Reference><Reference><Citation>Public Health England (PHE), Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2)  [(accessed on 3 June 2021)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991135/3_June_2021_Risk_assessment_for_SARS-CoV-2_variant_DELTA.pdf.</Citation></Reference><Reference><Citation>Mlcochova P., Kemp S., Dhar M.S., Papa G., Meng B., Mishra S., Whittaker Ch Mellan T., Ferreira I., Datir R., Collier D.A., et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. BioRxiv. 20212021 doi: 10.1101/2021.05.08.443253. Update in: mBio 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.08.443253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Johnson B.A., Xia H., Ku Z., Schindewolf C., Widen S.G., An Z., Weaver S.C., Menachery V.D., et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell. Rep. 2022;39:110829. doi: 10.1016/j.celrep.2022.110829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110829</ArticleId><ArticleId IdType="pmc">PMC9050581</ArticleId><ArticleId IdType="pubmed">35550680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P.D., Sapkal G.N., Abraham P., Ella R., Deshpande G., Patil D.Y., Nyayanit D.A., Gupta N., Sahay R.R., Shete A.M., et al. Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin. Infect. Dis. 2022;74:366&#x2013;368. doi: 10.1093/cid/ciab411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab411</ArticleId><ArticleId IdType="pubmed">33961693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A., McMenamin J., Taylor B., Robertson C., Public Health Scotland and the EAVE II Collaborators SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461&#x2013;2462. doi: 10.1016/S0140-6736(21)01358-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01358-1</ArticleId><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A., Irie T., Suzuki R., Maemura T., Nasser H., Uriu K., Kosugi Y., Shirakawa K., Sadamasu K., Kimura I., et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022;602:300&#x2013;306. doi: 10.1038/s41586-021-04266-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04266-9</ArticleId><ArticleId IdType="pmc">PMC8828475</ArticleId><ArticleId IdType="pubmed">34823256</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K., Kimura I., Shirakawa K., Takaori-Kondo A., Nakada T.A., Kaneda A., Nakagawa S., Sato K., Genotype to Phenotype Japan (G2P-Japan) Consortium Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. N. Engl. J. Med. 2021;385:2397&#x2013;2399. doi: 10.1056/NEJMc2114706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2114706</ArticleId><ArticleId IdType="pmc">PMC8609602</ArticleId><ArticleId IdType="pubmed">34731554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E., Hale C., Saito Y., Blachere N.E., Bergh M., Conlon E.G., Schaefer-Babajew D.J., DaSilva J., Muecksch F., Gaebler C., et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N. Engl. J. Med. 2021;384:2212&#x2013;2218. doi: 10.1056/NEJMoa2105000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105000</ArticleId><ArticleId IdType="pmc">PMC8117968</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Update on omicron. 28 November 2021.  [(accessed on 20 June 2023)].  Available online:  https://www.who.int/news/item/28-11-2021-update-on-omicron.</Citation></Reference><Reference><Citation>Global Initiative on Sharing Avian Influenza Dat (GISAID)  Tracking of Variants. 2021.  [(accessed on 20 June 2023)].  Available online:  https://www.gisaid.org/hcov19-variants/</Citation></Reference><Reference><Citation>Aleem A., Akbar Samad A.B., Slenker A.K. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)</Citation><ArticleIdList><ArticleId IdType="pubmed">34033342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou J., Lan W., Wu X., Zhao T., Duan B., Yang P., Ren Y., Quan L., Zhao W., Seto D., et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal. Transduct. Target. Ther. 2022;7:138. doi: 10.1038/s41392-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9039610</ArticleId><ArticleId IdType="pubmed">35474215</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim S.S.A., Karim Q.A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet. 2021;398:2126&#x2013;2128. doi: 10.1016/S0140-6736(21)02758-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02758-6</ArticleId><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Gilchuk P., Zost S.J., Binshtein E., Loes A.N., Hilton S.K., Huddleston J., Eguia R., Crawford K.H.D., et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell. Host Microbe. 2021;29:44&#x2013;57.e9. doi: 10.1016/j.chom.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., COVID-19 Genomics UK (COG-UK) Consortium SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409&#x2013;424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Chand M., et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679&#x2013;686. doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi F., Talebi Bezmin Abadi A. The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic. Int. J. Surg. 2022;99:106261. doi: 10.1016/j.ijsu.2022.106261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106261</ArticleId><ArticleId IdType="pmc">PMC8837492</ArticleId><ArticleId IdType="pubmed">35167986</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonager J., Bennedb&#xe6;k M., Bager P., Wohlfahrt J., Ellegaard K.M., Ingham A.C., Edslev S.M., Stegger M., Sieber R.N., Lassauniere R., et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Eurosurveillance. 2022;27:2200181. doi: 10.2807/1560-7917.ES.2022.27.10.2200181.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.10.2200181</ArticleId><ArticleId IdType="pmc">PMC8915403</ArticleId><ArticleId IdType="pubmed">35272746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.L., Abdullah S.M.U., Chan W.M., Chan B.P., Ip J.D., Chu A.W., Lu L., Zhang X., Zhao Y., Chuang V.W., et al. Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong. Nat. Commun. 2022;13:3618. doi: 10.1038/s41467-022-31395-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31395-0</ArticleId><ArticleId IdType="pmc">PMC9232516</ArticleId><ArticleId IdType="pubmed">35750868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Moir M., Everatt J., Giovanetti M., Scheepers C., Wilkinson E., Subramoney K., Makatini Z., Moyo S., Amoako D.G., et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 2022;28:1785&#x2013;1790. doi: 10.1038/s41591-022-01911-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01911-2</ArticleId><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalali N., Brustad H.K., Frigessi A., MacDonald E.A., Meijerink H., Feruglio S.L., Nyg&#xe5;rd K.M., R&#xf8; G., Madslien E.H., de Blasio B.F. Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants. Nat. Commun. 2022;13:5706. doi: 10.1038/s41467-022-33233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33233-9</ArticleId><ArticleId IdType="pmc">PMC9520116</ArticleId><ArticleId IdType="pubmed">36175424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudriavtsev A.V., Vakhrusheva A.V., Novoseletsky V.N., Bozdaganyan M.E., Shaitan K.V., Kirpichnikov M.P., Sokolova O.S. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. Viruses. 2022;14:1603. doi: 10.3390/v14081603.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081603</ArticleId><ArticleId IdType="pmc">PMC9394476</ArticleId><ArticleId IdType="pubmed">35893668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D., Lan T., He X., Liu J., Chen L., Baptista-Hon D.T., Zhang K., Wei X. SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm. 2022;3:e126. doi: 10.1002/mco2.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.126</ArticleId><ArticleId IdType="pmc">PMC8925644</ArticleId><ArticleId IdType="pubmed">35317190</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A., Lui B.G., Wallisch A.K., Bacher M., M&#xfc;hl J., Reinholz J., Ozhelvaci O., Beckmann N., G&#xfc;imil Garcia R.D.L.C., Poran A., et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine&#x2013;elicited human sera. Science. 2022;375:678&#x2013;680. doi: 10.1126/science.abn7591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7591</ArticleId><ArticleId IdType="pmc">PMC9836206</ArticleId><ArticleId IdType="pubmed">35040667</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.-H., Porrot F., Staropoli I., Lemoine F., et al. Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization. Nature. 2022;602:671&#x2013;675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O&#x2019;Connell A.-M. Effectiveness of COVID-19 Vaccines against the Omicron (B. 1.1. 529) Variant of Concern. MedRxiv. 2021:1&#x2013;16. doi: 10.1101/2021.12.14.21267615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.14.21267615</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Data &amp; Surveillance. [Updated 7 March 2022]  [(accessed on 20 June 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/</Citation></Reference><Reference><Citation>GovUK  Variants: Distribution of Cases Data, 20 May 2022 [Updated 24 June 2022]  [(accessed on 20 June 2023)]; Available online:  https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)  SARS-CoV-2 Variants of Concern as of 8 December 2022.  [(accessed on 20 June 2023)].  Available online:  https://www.ecdc.europa.eu/en/covid-19/variants-concern.</Citation></Reference><Reference><Citation>Pearson C.A.B., Russell T.W., Davies N.G., Kucharski A.J., CMMID COVID-19 Working Group. Edmunds W.J., Eggo R.M. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa. CMMID Repository 2021.  [(accessed on 20 June 2023)].  Available online:  https://cmmid.github.io/topics/covid19/sa-novel-variant.html.</Citation></Reference><Reference><Citation>Cavanaugh A.M., Fortier S., Lewis P., Arora V., Johnson M., George K., Tobias J., Lunn S., Miller T., Thoroughman D., et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program&#x2014;Kentucky, March 2021. Morb. Mortal. Wkly. Rep. 2021;70:639&#x2013;643. doi: 10.15585/mmwr.mm7017e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7017e2</ArticleId><ArticleId IdType="pmc">PMC8084128</ArticleId><ArticleId IdType="pubmed">33914720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugembe D.L., Phan M.V.T., Ssewanyana I., Semanda P., Nansumba H., Dhaala B., Nabadda S., O&#x2019;Toole &#xc1;.N., Rambaut A., Kaleebu P., et al. Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. Nat. Microbiol. 2021;6:1094&#x2013;1101. doi: 10.1038/s41564-021-00933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00933-9</ArticleId><ArticleId IdType="pmc">PMC8318884</ArticleId><ArticleId IdType="pubmed">34163035</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez C.E., Perdiguero B., Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines. 2021;9:243. doi: 10.3390/vaccines9030243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030243</ArticleId><ArticleId IdType="pmc">PMC7999234</ArticleId><ArticleId IdType="pubmed">33799505</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.A. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines. 2019;7:37. doi: 10.3390/vaccines7020037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7020037</ArticleId><ArticleId IdType="pmc">PMC6631684</ArticleId><ArticleId IdType="pubmed">31022829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Proc. Natl. Acad. Sci. USA. 1995;772:30&#x2013;39. doi: 10.1111/j.1749-6632.1995.tb44729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1995.tb44729.x</ArticleId><ArticleId IdType="pubmed">8546411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines-a new era in vaccinology. Nat. Rev. Drug. Discov. 2018;17:261&#x2013;279. doi: 10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 20 June 2023)].  Available online:  https://www.gavi.org/vaccineswork?gclid=Cj0KCQjwna2FBhDPARIsACAEc_Xs53mjrz5yZ4vp5vpsxMqzGQhoWQ0jVVFlviYNGFfXMz8VkFpQ-74aAm-KEALw_wcB.</Citation></Reference><Reference><Citation>Basta N.E., Moodie E.M.M., on behalf of the VIPER (Vaccines, Infectious disease Prevention, and Epidemiology Research) Group COVID-19 Vaccine Development and Approvals Tracker Team  COVID-19 Vaccine Tracker.  [(accessed on 20 June 2023)].  Available online:  https://covid19.trackvaccines.org/</Citation></Reference><Reference><Citation>Ramesh S., Govindarajulu M., Parise R.S., Neel L., Shankar T., Patel S., Lowery S.P., Smith F., Dhanasekaran M., Moore T. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines. 2021;9:1195. doi: 10.3390/vaccines9101195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101195</ArticleId><ArticleId IdType="pmc">PMC8537675</ArticleId><ArticleId IdType="pubmed">34696303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Jackson L., Khoury D.S., Khan K., Moyo-Gwete T., Tegally H., San J.E., Cromer D., Scheepers C., Amoako D., et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021 doi: 10.1101/2021.12.08.21267417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.08.21267417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm A., Widera M., Grikscheit K., Toptan T., Schenk B., Pallas C., Metzler M., Kohmer N., Hoehl S., Marschalek R., et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine. 2022;82:104158. doi: 10.1016/j.ebiom.2022.104158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104158</ArticleId><ArticleId IdType="pmc">PMC9271884</ArticleId><ArticleId IdType="pubmed">35834885</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Huo J., Zhou D., Zahradn&#xed;k J., Supasa P., Liu C., Duyvesteyn H.M.E., Ginn H.M., Mentzer A.J., Tuekprakhon A., et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467&#x2013;484.e15. doi: 10.1016/j.cell.2021.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O&#x2019;Connell A.M., et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532&#x2013;1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan S.A., Chung H., Brown K.A., Austin P.C., Fell D.B., Gubbay J.B., Nasreen S., Schwartz K.L., Sundaram M.E., Tadrous M., et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw. Open. 2022;5:e2232760. doi: 10.1001/jamanetworkopen.2022.32760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.32760</ArticleId><ArticleId IdType="pmc">PMC9500552</ArticleId><ArticleId IdType="pubmed">36136332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Schelde A.B., Moustsen-Helm I.R., Emborg H.-D., Krause T.G., M&#xf8;lbak K., Valentiner-Branth P. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv. 2021 doi: 10.1101/2021.12.20.21267966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.20.21267966</ArticleId></ArticleIdList></Reference><Reference><Citation>Europian Medicines Agency (EMA)  Adapted vaccine targeting BA.4 and BA.5 Omicron Variants and Original SARS-CoV-2 Recommended for Approval. [News 12 September 2022]  [(accessed on 20 June 2023)].  Available online:  https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval.</Citation></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Ayoub H.H., AlMukdad S., Yassine H.M., Al-Khatib H.A., Smatti M.K., Tang P., Hasan M.R., Coyle P., et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N. Engl. J. Med. 2022;386:1804&#x2013;1816. doi: 10.1056/NEJMoa2200797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200797</ArticleId><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S., Champion J., Moultrie H., Bekker L.G., Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N. Engl. J. Med. 2022;386:494&#x2013;496. doi: 10.1056/NEJMc2119270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119270</ArticleId><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.F., Ackerson B.K., Luo Y., Sy L.S., Talarico C.A., Tian Y., Bruxvoort K.J., Tubert J.E., Florea A., Ku J.H., et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 2022;28:1063&#x2013;1071. doi: 10.1038/s41591-022-01753-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId><ArticleId IdType="pmc">PMC9117141</ArticleId><ArticleId IdType="pubmed">35189624</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.G., Natarajan K., Irving S.A., Rowley E.A., Griggs E.P., Gaglani M., Klein N.P., Grannis S.J., DeSilva M.B., Stenehjem E., et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance&#x2014;VISION Network, 10 States, August 2021&#x2013;January 2022. Morb. Mortal. Wkly. Rep. 2022;71:139&#x2013;145. doi: 10.15585/mmwr.mm7104e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7104e3</ArticleId><ArticleId IdType="pmc">PMC9351525</ArticleId><ArticleId IdType="pubmed">35085224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B., Gao L., Zhou Q., Yu K., Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouro V., Fischer A. Dealing with a mucosal viral pandemic: Lessons from COVID-19 vaccines. Mucosal Immunol. 2022;15:584&#x2013;594. doi: 10.1038/s41385-022-00517-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-022-00517-8</ArticleId><ArticleId IdType="pmc">PMC9062288</ArticleId><ArticleId IdType="pubmed">35505121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., Stowe J., Tessier E., Groves N., Dabrera G., et al. Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021;385:585&#x2013;594. doi: 10.1056/NEJMoa2108891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreen S., Chung H., He S., Brown K.A., Gubbay J.B., Buchan S.A., Fell D.B., Austin P.C., Schwartz K.L., Sundaram M.E., et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat. Microbiol. 2022;7:379&#x2013;385. doi: 10.1038/s41564-021-01053-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01053-0</ArticleId><ArticleId IdType="pubmed">35132198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Lou J., Chan S.Y., Zheng H., Liu C., Zhao S., Li Q., Mok C.K.P., Chan R.W.Y., Chong M.K.C., et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat. Med. 2022;28:1715&#x2013;1722. doi: 10.1038/s41591-022-01877-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01877-1</ArticleId><ArticleId IdType="pmc">PMC9388371</ArticleId><ArticleId IdType="pubmed">35710987</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer Inc  Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age. [25 January 2022]  [(accessed on 17 December 2022)].  Available online:  https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based.</Citation></Reference><Reference><Citation>Spencer A.J., Morris S., Ulaszewska M., Powers C., Kailath R., Bissett C., Truby A., Thakur N., Newman J., Allen E.R., et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine. 2022;77:103902. doi: 10.1016/j.ebiom.2022.103902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103902</ArticleId><ArticleId IdType="pmc">PMC8881183</ArticleId><ArticleId IdType="pubmed">35228013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray G., Collie S., Goga A., Garrett N., Champion J., Seocharan I., Bamford L., Moultrie H., Bekker L.G. Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. N. Engl. J. Med. 2022;386:2243&#x2013;2245. doi: 10.1056/NEJMc2202061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202061</ArticleId><ArticleId IdType="pmc">PMC9093716</ArticleId><ArticleId IdType="pubmed">35507482</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe J., Andrews N., Kirsebom F., Ramsay M., Bernal J.L. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat. Commun. 2022;13:5736. doi: 10.1038/s41467-022-33378-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33378-7</ArticleId><ArticleId IdType="pmc">PMC9523190</ArticleId><ArticleId IdType="pubmed">36180428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gra&#xf1;a C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B.S., Probyn K., Villanueva G., Henschke N., et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;12:CD015477. doi: 10.1002/14651858.CD015477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015477</ArticleId><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov  Database.  [(accessed on 20 June 2023)]; Available online:  https://www.clinicaltrials.gov/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  COVID-19 Vaccine Effectiveness and Safety.  [(accessed on 20 June 2023)]; Available online:  https://www.cdc.gov/mmwr/covid19_vaccine_safety.html.</Citation></Reference><Reference><Citation>COVID-NMA  The COVID-NMA Initiative. A Living Mapping and Living Systematic Review of COVID-19 Trials.  [(accessed on 20 June 2023)].  Available online:  https://covid-nma.com/</Citation></Reference><Reference><Citation>World Health Organization (WHO)  International Clinical Trials Registry Platform (ICTRP)  [(accessed on 20 June 2023)].  Available online:  https://www.who.int/clinical-trials-registry-platform.</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Jr., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761&#x2013;1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sahly H.M., Baden L.R., Essink B., Doblecki-Lewis S., Martin J.M., Anderson E.J., Campbell T.B., Clark J., Jackson L.A., Fichtenbaum C.J., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N. Engl. J. Med. 2021;385:1774&#x2013;1785. doi: 10.1056/NEJMoa2113017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2113017</ArticleId><ArticleId IdType="pmc">PMC8482810</ArticleId><ArticleId IdType="pubmed">34551225</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881&#x2013;891. doi: 10.1016/S0140-6736(21)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00432-3</ArticleId><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 2021;385:2348&#x2013;2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., C&#xe1;rdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Polinski J.M., Weckstein A.R., Batech M., Kabelac C., Kamath T., Harvey R., Jain S., Rassen J.A., Khan N., Schneeweiss S. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. JAMA Netw. Open. 2022;5:e222959. doi: 10.1001/jamanetworkopen.2022.2959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.2959</ArticleId><ArticleId IdType="pmc">PMC8931562</ArticleId><ArticleId IdType="pubmed">35297969</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover M.D., Do&#x11f;anay H.L., Akova M., G&#xfc;ner H.R., Azap A., Akhan S., K&#xf6;se &#x15e;., Erdin&#xe7; F.&#x15e;., Akal&#x131;n E.H., Tabak &#xd6;.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213&#x2013;222. doi: 10.1016/S0140-6736(21)01429-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine. N. Engl. J. Med. 2021;385:1172&#x2013;1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Montastruc J.L., Biron P., Sommet A. NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression. Fundam. Clin. Pharmacol. 2022;36:1125&#x2013;1127. doi: 10.1111/fcp.12794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12794</ArticleId><ArticleId IdType="pmc">PMC9348229</ArticleId><ArticleId IdType="pubmed">35502459</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., Al Nusair M., Hassany M., Jawad J.S., Abdalla J., et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326:35&#x2013;45. doi: 10.1001/jama.2021.8565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Belayachi J., Yang Y., Fu Q., Rodewald L., Li H., Yan B., Wang Y., Shen Y., Yang Q., et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public. Health. 2022;22:1584. doi: 10.1186/s12889-022-14016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14016-9</ArticleId><ArticleId IdType="pmc">PMC9392069</ArticleId><ArticleId IdType="pubmed">35987605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem I., Ul Munamm S.A., Ur Rasool M., Fatimah M., Abu Bakar M., Rana Z.K., Khatana U.F., Jordon L., Saqlain M., Mahdi N., et al. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. Postgrad. Med. J. 2022;99:463&#x2013;469. doi: 10.1136/postgradmedj-2022-141649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2022-141649</ArticleId><ArticleId IdType="pubmed">37294716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R., Reddy S., Blackwelder W., Potdar V., Yadav P., Sarangi V., Aileni V.K., Kanungo S., Rai S., Reddy P., et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398:2173&#x2013;2184. doi: 10.1016/S0140-6736(21)02000-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02000-6</ArticleId><ArticleId IdType="pmc">PMC8584828</ArticleId><ArticleId IdType="pubmed">34774196</ArticleId></ArticleIdList></Reference><Reference><Citation>Behera P., Singh A.K., Subba S.H., Mc A., Sahu D.P., Chandanshive P.D., Pradhan S.K., Parida S.P., Mishra A., Patro B.K., et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum. Vaccin. Immunother. 2022;18:2034456. doi: 10.1080/21645515.2022.2034456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2034456</ArticleId><ArticleId IdType="pmc">PMC9009960</ArticleId><ArticleId IdType="pubmed">35321625</ArticleId></ArticleIdList></Reference><Reference><Citation>Shkoda A.S., Gushchin V.A., Ogarkova D.A., Stavitskaya S.V., Orlova O.E., Kuznetsova N.A., Keruntu E.N., Pochtovyi A.A., Pukhov A.V., Kleymenov D.A., et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines. 2022;10:938. doi: 10.3390/vaccines10060938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060938</ArticleId><ArticleId IdType="pmc">PMC9227631</ArticleId><ArticleId IdType="pubmed">35746546</ArticleId></ArticleIdList></Reference><Reference><Citation>Matveeva O., Ershov A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June-July 2021) Vaccines. 2022;10:984. doi: 10.3390/vaccines10070984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10070984</ArticleId><ArticleId IdType="pmc">PMC9320764</ArticleId><ArticleId IdType="pubmed">35891148</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin S.A., Ye L., MacKinnon-Cameron D., Smith B., Cahn P.E., Ruiz-Palacios G.M., Ikram A., Lanas F., Lourdes Guerrero M., Mu&#xf1;oz Navarro S.R., et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399:237&#x2013;248. doi: 10.1016/S0140-6736(21)02753-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02753-7</ArticleId><ArticleId IdType="pmc">PMC8700283</ArticleId><ArticleId IdType="pubmed">34953526</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicago Inc  Product Monograph Including Patient Medication Information Covifenz&#xae; COVID-19 Vaccine (Plant-Based Virus-like Particles [VLP.; Recombinant, Adjuvanted) 2022.  [(accessed on 20 June 2023)].  Available online:  https://covid-vaccine.canada.ca/info/pdf/covifenz-pm-en.pdf.</Citation></Reference><Reference><Citation>Rotshild V., Hirsh-Raccah B., Miskin I., Muszkat M., Matok I. Comparing the clinical efficacy of COVID-19 vaccines: A systematic review and network meta-analysis. Sci. Rep. 2021;11:22777. doi: 10.1038/s41598-021-02321-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02321-z</ArticleId><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2022;28:202&#x2013;221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi W.Y., Li Y.D., Huang H.C., Chan T.E.H., Chow S.Y., Su J.H., Ferrall L., Hung C.F., Wu T.C. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci. 2022;29:82. doi: 10.1186/s12929-022-00853-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00853-8</ArticleId><ArticleId IdType="pmc">PMC9569411</ArticleId><ArticleId IdType="pubmed">36243868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Kaperak C., Sato T., Sakuraba A. COVID-19 Reinfection: A Rapid Systematic Review of Case Reports and Case Series. J. Investig. Med. 2021;69:1253&#x2013;1255. doi: 10.1136/jim-2021-001853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-001853</ArticleId><ArticleId IdType="pubmed">34006572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nainu F., Abidin R.S., Bahar M.A., Frediansyah A., Emran T.B., Rabaan A.A., Dhama K., Harapan H. SARS-CoV-2 reinfection and implications for vaccine development. Hum. Vaccin. Immunother. 2020;16:3061&#x2013;3073. doi: 10.1080/21645515.2020.1830683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1830683</ArticleId><ArticleId IdType="pmc">PMC8641611</ArticleId><ArticleId IdType="pubmed">33393854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S., Shlezinger R., Perez G., Lotan R., Peretz A., Ben-Tov A., Herzel E., Alapi H., Cohen D., Muhsen K., et al. The Incidence of SARS-CoV-2 Reinfection in Persons with Naturally Acquired Immunity with and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine: A Retrospective Cohort Study. Ann. Intern. Med. 2022;175:674&#x2013;681. doi: 10.7326/M21-4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4130</ArticleId><ArticleId IdType="pmc">PMC8855786</ArticleId><ArticleId IdType="pubmed">35157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanaugh A.M., Spicer K.B., Thoroughman D., Glick C., Winter K. Reduced Risk of Reinfection with SARS-CoV-2. CoV-2 After COVID-19 Vaccination&#x2014;Kentucky, May-June 2021. Morb. Mortal. Wkly. Rep. 2021;70:1081&#x2013;1083. doi: 10.15585/mmwr.mm7032e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7032e1</ArticleId><ArticleId IdType="pmc">PMC8360277</ArticleId><ArticleId IdType="pubmed">34383732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S., Shlezinger R., Perez G., Lotan R., Peretz A., Ben-Tov A., Herzel E., Alapi H., Cohen D., Muhsen K., et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clin. Infect. Dis. 2022;75:e545&#x2013;e551. doi: 10.1093/cid/ciac262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac262</ArticleId><ArticleId IdType="pmc">PMC9047157</ArticleId><ArticleId IdType="pubmed">35380632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Michlmayr D., Gubbels S.M., M&#xf8;lbak K., Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study. Lancet. 2021;397:1204&#x2013;1212. doi: 10.1016/S0140-6736(21)00575-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00575-4</ArticleId><ArticleId IdType="pmc">PMC7969130</ArticleId><ArticleId IdType="pubmed">33743221</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Hasan M.R., Ayoub H.H., Qassim S., AlMukdad S., Coyle P., Yassine H.M., Al-Khatib H.A., Benslimane F.M., et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N. Engl. J. Med. 2022;386:1288&#x2013;1290. doi: 10.1056/NEJMc2200133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2200133</ArticleId><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen K.F., Moustsen-Helms I.R., Schelde A.B., Gram M.A., Emborg H.D., Nielsen J., Hansen C.H., Andersen M.A., Meaidi M., Wohlfahrt J., et al. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Med. 2022;19:e1004037. doi: 10.1371/journal.pmed.1004037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004037</ArticleId><ArticleId IdType="pmc">PMC9681105</ArticleId><ArticleId IdType="pubmed">36413551</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco M.E., Acuti Martellucci C., Baccolini V., De Vito C., Renzi E., Villari P., Manzoli L. COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis. Front. Med. 2022;9:1023507. doi: 10.3389/fmed.2022.1023507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1023507</ArticleId><ArticleId IdType="pmc">PMC9681813</ArticleId><ArticleId IdType="pubmed">36438045</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeimi R., Sepidarkish M., Mollalo A., Parsa H., Mahjour S., Safarpour F., Almukhtar M., Mechaal A., Chemaitelly H., Sartip B., et al. SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. EClinicalMedicine. 2023;56:101786. doi: 10.1016/j.eclinm.2022.101786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101786</ArticleId><ArticleId IdType="pmc">PMC9795163</ArticleId><ArticleId IdType="pubmed">36590788</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es D., Pissarra R., Reis-Melo A., Guimar&#xe3;es H. Multisystem inflammatory syndrome in children (MISC): A systematic review. Int. J. Clin. Pract. 2021;75:e14450. doi: 10.1111/ijcp.14450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14450</ArticleId><ArticleId IdType="pubmed">34105843</ArticleId></ArticleIdList></Reference><Reference><Citation>Riechotta V., Siemens W., Thielemann I., Toews M., Koch J., Vygen-Bonnet S., Kothari K., Grummich K., Braun C., Kapp P., et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: A systematic review and meta-analysis. Lancet Child Adolesc. Health. 2023;7:379&#x2013;391. doi: 10.1016/S2352-4642(23)00078-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00078-0</ArticleId><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="pubmed">37084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre D.W., Lumley S.F., Wei J., Cox S., James T., Justice A., Jesuthasan G., O&#x2019;Donnell D., Howarth A., Hatch S.B., et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer -BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Clin. Microbiol. Infect. 2021;27:1516.e7&#x2013;1516.e14. doi: 10.1016/j.cmi.2021.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.041</ArticleId><ArticleId IdType="pmc">PMC8180449</ArticleId><ArticleId IdType="pubmed">34111577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed A.H., Blebil A., Dujaili J., Rasool-Hassan B.A. The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients. AIDS Rev. 2020;22:151&#x2013;157. doi: 10.24875/AIDSRev.20000052.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/AIDSRev.20000052</ArticleId><ArticleId IdType="pubmed">33118527</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan A., Siglin J., Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020;9:9205&#x2013;9218. doi: 10.1002/cam4.3534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3534</ArticleId><ArticleId IdType="pmc">PMC7774721</ArticleId><ArticleId IdType="pubmed">33078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.R.Y.B., Wong S.Y., Chai L.Y.A., Lee S.C., Lee M.X., Muthiah M.D., Tay S.H., Teo C.B., Tan B.K.J., Chan Y.H., et al. Efficacy of COVID-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ. 2022;376:e068632. doi: 10.1136/bmj-2021-068632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tormen M., Taliento C., Salvioli S., Piccolotti I., Scutiero G., Cappadona R., Greco P. Effectiveness and safety of COVID-19 vaccine in pregnant women: A systematic review with meta-analysis. BJOG. 2023;130:348&#x2013;357. doi: 10.1111/1471-0528.17354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.17354</ArticleId><ArticleId IdType="pmc">PMC9878107</ArticleId><ArticleId IdType="pubmed">36444098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen S.C., Hernandez A., Fell D.B., Austin P.C., D&#x2019;Souza R., Guttmann A., Brown K.A., Buchan S.A., Gubbay J.B., Nasreen S., et al. Maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: Test negative design study. BMJ. 2023;380:e074035. doi: 10.1136/bmj-2022-074035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074035</ArticleId><ArticleId IdType="pmc">PMC9903336</ArticleId><ArticleId IdType="pubmed">36754426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R., Yeni C.M., Utami N.A., Masand R., Asrani R.K., Patel S.K., Kumar A., Yatoo M.I., Tiwari R., Natesan S., et al. SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies-a narrative review. J. Infect. Public. Health. 2021;14:863&#x2013;875. doi: 10.1016/j.jiph.2021.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.04.005</ArticleId><ArticleId IdType="pmc">PMC8062420</ArticleId><ArticleId IdType="pubmed">34118736</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller I.F., Metcalf C.J.E. Assessing the Risk of Vaccine-Driven Virulence Evolution in SARS-CoV-2. R. Soc. Open Sci. 2022;9:211021. doi: 10.1098/rsos.211021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsos.211021</ArticleId><ArticleId IdType="pmc">PMC8728167</ArticleId><ArticleId IdType="pubmed">35070341</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoutzias G.D., Nikolaidis M., Tryfonopoulou E., Chlichlia K., Markoulatos P., Oliver S.G. The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. Viruses. 2022;14:78. doi: 10.3390/v14010078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010078</ArticleId><ArticleId IdType="pmc">PMC8778387</ArticleId><ArticleId IdType="pubmed">35062282</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014&#x2013;1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cells. 2020;181:281&#x2013;292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Velikova T.V., Kotsev S.V., Georgiev D.S., Batselova H.M. Immunological aspects of COVID-19: What do we know? World J. Biol. Chem. 2020;11:14&#x2013;29. doi: 10.4331/wjbc.v11.i2.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.4331/wjbc.v11.i2.14</ArticleId><ArticleId IdType="pmc">PMC7520644</ArticleId><ArticleId IdType="pubmed">33024515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>